Recommendations for the use of eltrombopag in patients with thrombocytopenia due to chemotherapy

Eltrombopag (eltrombopag ethanolamine tablets) is a common treatment option when chemotherapy causes thrombocytopenia.

Before using eltrombopag, the patient's chemotherapy regimen, degree of thrombocytopenia, bleeding risk, and concomitant diseases should be comprehensively evaluated. Ensure that patients meet the indications for eltrombopag, that is, adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and poor response to glucocorticoids, immunoglobulins and other treatments.

The initial dose of eltrombopag is usually 25 mg to 50 mg once daily, depending on the patient's specific condition. In patients with moderate or severe hepatic impairment, it is recommended to start with a lower dose.

During treatment, platelet counts should be monitored regularly and dosage adjusted based on patient response. If the platelet count is lower than 50×10^9/L for two consecutive weeks, the dose can be increased by 25mg once daily every two weeks, but the maximum daily dose is not recommended to exceed 75mg.

Eltrombopag should be taken on an empty stomach, i.e. at least 1 hours before a meal or 2 hours after a meal. This helps ensure adequate absorption of the medication.

While taking eltrombopag, routine blood tests, especially platelet count, should be monitored regularly. This helps evaluate drug efficacy and adjust treatment plans in a timely manner. Because eltrombopag may have certain effects on the liver, regular monitoring of liver function is recommended during treatment. Pay close attention to patients' adverse reactions during use of eltrombopag, such as headache, loss of appetite, nausea, vomiting, etc. If symptoms are severe or persist, seek medical attention promptly.

When the platelet count stabilizes and reaches a safe level, the drug can be gradually discontinued under the guidance of a doctor. Platelet counts should continue to be monitored during drug withdrawal to prevent rebound. If the treatment effect of eltrombopag is not good or the patient develops intolerance, he should communicate with the doctor in time and consider changing the drug or adjusting the treatment plan.

While taking eltrombopag, patients should keep a light diet and avoid spicy and irritating foods. At the same time, be careful not to take it at the same time with food or drugs that may affect the efficacy of the medicine. Avoid strenuous exercise and trauma to reduce the risk of bleeding. Maintaining adequate sleep and a good attitude can also help improve the effectiveness of treatment.